



# FLOURISH

RESEARCH

## Curriculum Vitae

### Mohammad Reza Bolouri, MD

10801 Monroe Road, Suite 100 Matthews, NC 28105  
Tel: (704) 364-4000 E-Mail: [mrbolouri@flourishresearch.com](mailto:mrbolouri@flourishresearch.com)

#### EDUCATION

2003-2004 Chief Resident in Neurology, Allegheny General Hospital, Pittsburgh, PA  
2001-2003 Residency in Neurology, Allegheny General Hospital, Pittsburgh, PA  
1999-2001 Residency in Psychiatry, St. Francis Medical Center, Pittsburgh, PA  
1990 Doctor of Medicine, Mundial University, Santo Domingo, Dominican Republic  
1985 BA, Chemistry / PreMed, Florida Atlantic University, Boca Raton, FL

#### LICENSE(S)

2004- Present North Carolina, 200400301

#### CERTIFICATION(S)

Sep 2005 - Present Board-Certified Neurologist

#### PROFESSIONAL EXPERIENCE

2023 – Present Medical Director, AMC Research, LLC dba Flourish Research, Matthews, NC  
2020 – 2023 Medical Director, AMC Research, LLC, Matthews, NC  
2008 – Present Medical Director, Alzheimer's Memory Center, Matthews, NC  
2008 – 2010 Principal Investigator, Carolinas Research Associates, Charlotte, NC  
2006 – 2008 Director of Alzheimer's & Memory Care, Presbyterian Neurology Center Charlotte, NC  
2004 – 2006 Director of Cognitive Disorders, Neurology Consultants of the Carolinas, Charlotte, NC  
1991 – 1999 Director of Research, Baumel-Eisner Neuromedical Institute, Miami, FL

#### TRAINING

Oct 2020 Collaborative Institutional Training Initiative (CITI)/Good Clinical Practice (GCP)

#### PSYCHOMETRIC RATING/SCALES EXPERIENCE

C-SSRS  
ADAS-Cog  
ADCS-ADL  
MMSE  
NPI  
CDR

#### CLINICAL RESEARCH TRIALS CONDUCTED:

## ***Alzheimer's Disease***

1. A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease (TargetTau-1) – Principal Investigator - 2024
2. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease – Principal Investigator - 2024
3. A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous ACU193 In Early Alzheimer's Disease – Principal Investigator - 2024
4. Open-Label Extension to a Randomized, Double-blind, Sham-controlled, Adaptive-Design Pivotal Study of Sensory Stimulation in Subjects with Alzheimer's Disease – Principal Investigator - 2024
5. Long-term Extension of a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype – Principal Investigator - 2024
6. A Phase 2, Parallel Group, Randomized, Double-blind, Placebo-controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with early Alzheimer's Disease – Principal Investigator - 2024
7. A Phase IB/IIA, Randomized, Double-blind, Placebo-controlled, Multiple-ascending Dose, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients with Prodromal or Mild to Moderate Alzheimer's Disease – Principal Investigator - 2024
8. A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer's Disease – Principal Investigator - 2024
9. A Phase 2, Randomized, Multicenter, Two-Arm, Open-label Study to Compare the Pharmacodynamics, Safety, and Tolerability of Subcutaneous versus Intravenous Administration of Aducanumab (BIIB037) in Participates with Alzheimer's Disease – Principal Investigator - 2023
10. A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer's Disease – Principal Investigator - 2023
11. A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of mild to Moderate Alzheimer's Disease – Principal Investigator - 2023
12. Assessment of Safety and Efficacy Measured by Amyloid Reduction of Remternetug in Early Symptomatic Alzheimer's Disease – Principal Investigator - 2023
13. Open-label Extension Study of PRX012 in Subjects with Alzheimer's Disease Who Were Enrolled in the Study PRX012-101 or PRX012-102 – Principal Investigator - 2023
14. A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Multiple Dose Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of PRX012 in Subjects with Alzheimer's Disease – Principal Investigator - 2023

15. A Multi-center Open-label Long Term Extension Study to Assess the Safety of TB006 in Patients who have Completed Protocol TB006AD2102 and in De Novo Patients with Alzheimer's Disease – Principal Investigator - 2023
16. An Open-label, Long-Term Extension Study to Evaluate the Safety and Tolerability of Simufilam 100 mg tablets in Participants with Mild to Moderate Alzheimer's Disease – Principal Investigator - 2023
17. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in subjects with Mild to Moderate Alzheimer's Disease – Principal Investigator - 2023
18. A Phase 2a/2b, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer's Disease Dementia – Principal Investigator - 2023
19. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of BII080 in Subjects with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia – Principal Investigator - 2022
20. A Phase 3b/4 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Verify the Clinical Benefit of Aducanumab (BII037) in Participants with Alzheimer's Disease – Principal Investigator - 2022
21. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects with Mild-to-Moderate Alzheimer's Disease – Principal Investigator - 2022
22. A Phase 1 Placebo-controlled, Single- and Multiple-dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous ACU193 in Mild Cognitive Impairment or Mild Dementia due to Alzheimer's Disease – Principal Investigator - 2022
23. Randomized, Delayed Start, Double Blind, Parallel Group, Placebo Controlled, Multicenter Study of Piromelatine 20 mg in Participants with Mild Dementia Due to Alzheimer's Disease – Principal Investigator - 2022
24. A Randomized, Double-Blind, Sham-Controlled, Adaptive- Design Pivotal Study of Sensory Stimulation in Subjects with Alzheimer's Disease (Hope Study) – Principal Investigator - 2022
25. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BII080 in Subjects with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia – Principal Investigator - 2022
26. A Phase III, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease – Principal Investigator - 2022
27. A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to evaluate the Efficacy and Safety of Intravenous ACU193 in Early Alzheimer's Disease – Principal Investigator - 2022
28. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects with Mild-To-Moderate Alzheimer's Disease – Principal Investigator - 2022
29. International Collaboration for Real-World Evidence in Alzheimer's Disease (ICARE AD) – A Prospective Real-World Observational Study of Aducanumab-avwa in Patients with Alzheimer's Disease in the US –

Principal Investigator - 2022

30. A Seamless Phase 1b/2a Double-blind, Randomized, Multiple Dose, Multi-center, Sequential Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of TB006 in Patients with Mild to Severe Alzheimer's Disease – Principal Investigator 2022
31. A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Study of NE3107 in Subjects Who Have Mild to Moderate Probable Alzheimer's Disease – Principal Investigator - 2021
32. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype – Principal Investigator - 2021
33. Open-Label Extension of Studies ATH-1017-AD-0201 and ATHE-1017-AD-0202 in Subjects with Mild to Moderate Alzheimer's Disease – Principal Investigator - 2021
34. A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease – Principal Investigator - 2021
35. AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study with and Extension Phase to Evaluate Efficacy and Safety of Treatment with BAN2401 in Subjects with Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects with Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) – Principal Investigator - 2021
36. A Randomised Double-Blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects with Early Alzheimer's Disease (EVOKE plus) – Principal Investigator - 2021
37. A Randomised Double-Blind Placebo-Controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects with Early Alzheimer's Disease (EVOKE) – Principal Investigator - 2021
38. An Open-Label, Multicenter, Rollover Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants with Alzheimer's Disease – Principal Investigator - 2021
39. Assess of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease – Principal Investigator - 2020
40. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability, and long-term Efficacy of Bryostatins in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment – Principal Investigator - 2020
41. An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants with Alzheimer's Disease – Principal Investigator - 2020
42. A phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease (GREEN MEMORY: GREEN Valley 971 Evaluation Memory) – Principal Investigator - 2020
43. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302, and 221AD205 – Principal Investigator - 2020
44. A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects with Mild-to-Moderate Alzheimer's Disease – Principal Investigator - 2020

45. Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of Hydromethylthionine Mesylate (LMTM) Monotherapy in Subjects with Alzheimer's Disease Followed by a 12-Month Open-Label Treatment – Principal Investigator - 2020
46. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study with an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects with Early Alzheimer's Disease – Principal Investigator - 2019
47. Randomized, Double-Blind, Placebo Controlled, Multicenter Studies to Evaluate the Safety and Efficacy of Azeliragon as a Treatment for Subjects with Mild Alzheimer's Disease and Impaired Glucose Tolerance – Principal Investigator - 2019
48. A Randomized, Double-Blind, Placebo-Controlled Study of COR388 HCl in Subjects with Alzheimer's Disease – Principal Investigator - 2019
49. A Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Stage Alzheimer's Disease – Principal Investigator - 2019
50. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 In Subjects with Mild to Moderate Alzheimer's Disease – Principal Investigator - 2018
51. A Multi-Centre, Double-Blind, Parallel-Group, Randomised Controlled Study to Investigate Efficacy and Safety of Orally Administered BI 425809 During a 12-Week Treatment Period Compared to Placebo in Patients with Cognitive Impairment Due to Alzheimer's Disease – Principal Investigator - 2018
52. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer's Disease – Principal Investigator - 2018
53. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects No Receiving Memantine Treatment – Principal Investigator - 2018
54. A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects with Mild Alzheimer's Disease – Principal Investigator - 2018
55. A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study) – Principal Investigator - 2018
56. ADVANCE: Addressing Dementia Via Agitation-Centered Evaluation – A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects with Dementia of the Alzheimer's Type – Principal Investigator - 2018
57. A Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic at Risk for Developing Alzheimer's Dementia – Principal Investigator - 2018
58. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD) – Principal Investigator - 2018
59. A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of

- NPT088 in Patients with Probable Alzheimer's Disease – Principal Investigator - 2018
60. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects with Mild to Moderate Alzheimer's Disease Dementia and Irregular Sleep-Wake Rhythm Disorder – Principal Investigator - 2017
  61. A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer's Disease – Principal Investigator - 2017
  62. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects Diagnosed with MCI Due to AD with Intermediate Likelihood/Prodromal AD – Principal Investigator - 2017
  63. Open Label Extension Study of Continued Safety and Efficacy Evaluation of Azeliragon in Patients with Mild Alzheimer's Disease – Principal Investigator - 2017
  64. Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US) – Principal Investigator - 2017
  65. A Double-Blind, placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment for Agitation and Aggression in Alzheimer's Disease – Principal Investigator - 2016
  66. Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral 18F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia – Principal Investigator – 2016
  67. A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease – Principal Investigator – 2016
  68. A Long-Term, Open Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Alzheimer's Disease – Principal Investigator – 2016
  69. A Phase 3, Double Blind, Randomized Study of RVT-101 versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects with Mild to Moderate Alzheimer's Disease – Principal Investigator – 2016
  70. A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects with Dementia with Lewy Bodies (DLB) – Principal Investigator – 2016
  71. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease - Principal Investigator – 2016
  72. A Phase 2A Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-
  73. Controlled Study of 50 MG and 100 MG of SUVN-502 in Subjects with Moderate Alzheimer's Disease Currently Treated with Donepezil Hydrochloride and memantine Hydrochloride – Principal Investigator – 2016
  74. A Phase 3, Multicenter, Long-Term, Extension Study of the Safety and Efficacy of AVP-786 {deuterated[d6]dextromethorphan hydrobromide [dd6-DM]/quinidine sulfate [Q]} for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type – Principal Investigator – 2016
  75. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability Of AVP-786 ([d6-DM]/quinidine sulfate [Q]) for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type – Principal Investigator – 2016
  76. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate

the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease – Principal Investigator – 2016

77. A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects with Agitation Associated with Dementia of the Alzheimer's Type who were Previously Treated with Brexpiprazole (OPC-34712) or Placebo in a Phase 3, Double-Blind Trial – Principal Investigator – 2016
78. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderate Severe to Severe Alzheimer's Disease – Principal Investigator – 2016
79. A Randomized, Double-Blind, Placebo-Controlled, Two Cohort Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease – Principal Investigator – 2016
80. A Placebo-Controlled, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-Finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects with Early Alzheimer's Disease – Principal Investigator – 2015
81. Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study of Ly AE58054 in Patients with Mild-Moderate Alzheimer's Disease Treated with an Acetylcholinesterase Inhibitor; Study 3 – Principal Investigator – 2015
82. A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer's Disease – Principal Investigator – 2015
83. A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Flexible Dosing of Brexpiprazole (OPC34712) in the Treatment of Subjects with Agitation Associated with Dementia of the Alzheimer's Type – Principal Investigator – 2015
84. Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients with Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine – Principal Investigator – 2016
85. A Phase 2, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof of Concept, Dose-Finding Study to Evaluate Safety, Tolerability and Efficacy of E2609 in subjects with Mild Cognitive impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild Dementia Due to Alzheimer's Disease – Principal Investigator – 2015
86. Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety & Tolerability of LU AE58054 as Adjunctive Treatment to Donepezil in Patients with Mild-Moderate Alzheimer's Disease – Principal Investigator – 2015
87. Phase 2, 26 Week Extension Study of the Safety & Clinical Effects of EVP-6124 in Subjects with Alzheimer's Disease Currently or previously Receiving an Acetylcholinesterase Inhibitor Medication – Principal Investigator – 2014
88. Phase 2, Multi-Center, Double-Blind, Parallel-Group, Randomized Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI409306 During a 12-Week Treatment Period Compared to Donepezil & Placebo in Patients with Cognitive Impairment Due to Alzheimer's Disease – Principal Investigator – 2014
89. Phase 2, Multi-Center, Double-Blind, Parallel-Group, Randomized Controlled Study to Investigate the

- Efficacy, Safety & Tolerability of Orally Administered BI409306 During a 12-Week Treatment Period Compared to Placebo in Patients with Alzheimer's Disease – Principal Investigator – 2014
90. Phase 2/3, 24 Month, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of aZD3293 in Early Alzheimer's Disease – Principal Investigator – 2014
  91. Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo controlled, fixed-Dose Study of LU AE58054 in Patients with Mild-Moderate Alzheimer's Disease Currently or Previously Receiving and Acetylcholinesterase Inhibitor Medication – Principal Investigator – 2014
  92. Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26 Week Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication – Principal Investigator – 2014
  93. Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy and Safety Study of Gantenerumab in Patients with Mild Alzheimer's Disease – Principal Investigator – 2014
  94. Phase 2, 36 Week Safety Extension of ELND005 for Treatment of Agitation and Aggression in Patients with Moderate to Severe Alzheimer's Disease – Principal Investigator – 2014
  95. Phase III, Randomized, Double-Blind Trial to Study the Efficacy & Safety of MK-8931 in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD) – Principal Investigator – 2014
  96. Phase IIa/IIb, Randomized, Double-Blind Trial to Evaluate the Efficacy & Safety of MK7622 as Adjunctive Therapy to Donepezil for Symptomatic Treatment in Subjects with Alzheimer's Disease – Principal Investigator – 2013
  97. Phase 2 Randomized, Double-Blind Trial to Evaluate the Efficacy & Safety of Oral ELND005 for Treatment of Agitation & Aggression in Patients with Moderate to Severe Alzheimer's Disease – Principal Investigator – 2013
  98. Phase 2-3, A 26-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigator the Effects Daily Administration of AC-1204 in Participants with Mild to Moderate Alzheimer's Disease (AD) with an Optional 26-Week Open-Label Extension – Principal Investigator – 2013
  99. Phase 2-3, Double-Blind, Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease – Principal Investigator – 2012  
Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effects of Subcutaneous RO4909832 in Cognition and Function in Prodromal Alzheimer's Disease with Option for up to an Additional two Years of Treatment and UP to Three Years of an Open-Label Extension with Active Study Treatment – Principal Investigator - 2012
  100. Phase IV Registry Trial for Mild to Moderate Alzheimer's Disease – Principal Investigator – 2012
  101. Retrospective Chare Review Study for Mild to Moderate Alzheimer's Disease – Principal Investigator – 2012
  102. Phase III Double-Blind Trial to Evaluate the Safety and Efficacy of Intravenous Bapineuzumab on Subjects with Mild to Moderate Alzheimer's Disease – Principal Investigator – 2011
  103. Phase IV Open-Label Study Comparing the Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type – Principal Investigator – 2010

104. Phase 2a Double-Blind Study to Evaluate the Efficacy and Safety of T-817Maa in Patients with Mild to Moderate Alzheimer's Disease – Principal Investigator – 2009
105. Phase IV Double-Blind Study Comparing the Effects of a Rivastigmine Patch on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type – Principal Investigator – 2009
106. Phase 3 Long-Term Extension Trial to Evaluate the Long-Term Safety & Tolerability of Dimebon in Patients with Alzheimer's Disease - Principal Investigator – 2009
107. Focus Group and Cognitive Debriefing Assessment of Day-to-Day Health Status in Alzheimer's Disease: Patients and Caregivers – Principal Investigator – 2009
108. Phase II Study is to Evaluate the Safety and Efficacy in Subjects with Mild to Moderate Alzheimer's Disease - Sub-Investigator – 2006
109. Phase II Trial for the Symptomatic Treatment of Alzheimer's Disease – Sub-Investigator – 2006
110. Phase II Study in Neutralizing Antibody Testing in Multiple Sclerosis Patients Receiving High Dose IFN Therapy – Sub-Investigator – 2006
111. Phase II Early Parkinson's Disease – Sub-Investigator – 2006
112. Phase II Autologous T Cell Vaccine Multiple Sclerosis – Sub-Investigator – 2005 - 2006
113. Phase III Study in Relapsing Remitting Multiple Sclerosis – Sub-Investigator – 2006

#### ***Trials Conducted from 1991-1999***

1. Efficacy and Safety of Depakote in Migraine Prophylaxis
2. Open Label Study of Tiagabine LCL in Patients with Epilepsy
3. Double-Blind Study of Safety and Efficacy in Alzheimer's Patients
4. Randomized, Double-Blind Comparison Study in Subjects with Painful Diabetic Polyneuropathy
5. Randomized, Double-Blind study in Patients with Mild to Moderate Alzheimer's Disease
6. Dose Ranging Safety and Tolerability Pilot Study of Remacemide Hydrochloride in Subjects with Probable Alzheimer's Disease
7. Double-Blind, Inpatient Study of Tizanidine Tablets for Spasticity Due to Multiple Sclerosis
8. Study of Alzene in Alzheimer's Patients with Mild to Moderately Severe Cognitive Decline
9. Study of Delay in Nursing Home Placement of Alzheimer's Disease Patients Treated in the Aricept Clinical Program
10. Open Label Study of Metrifonate in Patients with Probable Alzheimer's Disease – 7 Protocols
11. Study of Buspirone Hydrochloride EX in Patients with Generalized Anxiety Disorder – 2 Protocols
12. Study of Talsaclidine in Patients with Alzheimer's Disease – 2 Protocols
13. Pilot Study for the Treatment of Symptoms of Mild Dementia of the Alzheimer's Type
14. Placebo-controlled Study in Alzheimer's Type Demented Patients
15. Study of Nefazodone in the Treatment of Patients with Mood Disorders
16. Study of Nefazodone in the Treatment of Elderly Depressed Patients
17. Study of Oxiracetam in the Treatment of Multiple Infarct Dementia Mild to Moderate Severity, Low Dose Schedule
18. Study of Oxiracetam in the Treatment of Primary Degenerative Dementia of Mild to Moderate Severity, Low

## Dose Schedule and High Dose Schedule

19. Evaluation of Study Drug in Patients with Alzheimer's Disease
20. Study of Doneprzil Hydrochloride in Patients with Persistent Mild to Moderate Memory Impairments Resulting from a Single Closed Head Injury
21. Study of Doneprzil Hydrochloride in Patients with Alzheimer's Disease – 9 Protocols
22. Study of Doneprzil Hydrochloride in Patients with Dementia Associated with Cerebrovascular Disease – 2 Protocols
23. Study of Olanzapine on Cognitive Symptoms in Patients with Mild to Moderate Alzheimer's Disease without Psychosis
24. Comparison Study of Fluoxetine in Major Depressive Disorder
25. Study of Olanzapine for the Treatment of Psychosis and Associated Behavioral Disturbances in Patients with Dementia
26. Study of Olanzapine for the Treatment of Resistant Depression without Psychotic Features
27. Study of the Long Term Administration of Oral Physostigmine in Alzheimer's Disease and Senile Dementia of The Alzheimer's Type
28. Study of Memantine in Moderate to Severe Dementia of the Alzheimer's Type – 3 Protocols
29. Study of Ondansetron in the Treatment of Alzheimer's Type Dementia
30. Study of Combined Regimen of Subcutaneous and Oral Study Medication in the Prevention of Migraine Recurrence
31. Study of Ondansetron in the Treatment of Panic Disorder
32. Study of Mantane in Patients with Alzheimer's Disease
33. Studies of Lazabemide in Patients with Alzheimer's Disease – 2 Protocols
34. Study of Sabeluzone in the Treatment of Dementia of the Alzheimer's Type – 2 Protocols
35. Studies pf Galantamine in the Treatment of Alzheimer's Disease – 7 Protocols
36. Study of Sinemet CR in Parkinson's Disease for Patients on no Prior Levodopa Therapy
37. Compassionate Use of Sinemet CR in Advanced Parkinson's Disease
38. Study of Nimodipine in Prophylactic Treatment of Migraine Headaches – 4 Protocols
39. Study of Memantine for Moderately Severe to Severe Alzheimer's Disease
40. Study of IV & Oral Administration of Nimodipine for the Treatment of Acute Ischemic Brain Infarction
41. Study of Nimodipine for the Treatment of Cognitive, behavioral and Effective Impairments in Primary Degenerative Dementia
42. Study of Nimodipine for the Treatment of Multi-Infarct Dementia
43. Phase 3 Study of Nimodipine for the Treatment of Primary Degenerative Disorder
44. Compassionate use of Nimodipine for the Treatment of Primary Degenerative Disorder
45. Study of Nimodipine for the Treatment of Probable Alzheimer's Disease – 2 Protocols
46. Study of the Effect of Exelon on the Time to Clinical Diagnosis of Alzheimer's Disease in Subjects with Mild Cognitive Impairment
47. Study of Remeron for Major Depressive Disorder Who are at Least 65 Years of Age
48. Study of Sertraline for Treatment of Panic Disorder – 2 Protocols
49. Studies of Sandoz ENA 713 for the Treatment of Probable Alzheimer's Disease – 4 Protocols

50. Study of Paroxetine for the Treatment of Major Depressive Disorder
51. Studies of Ipratropium for the Treatment of Probable Alzheimer's Disease – 7 Protocols
52. Study of Alprazolam for the Treatment of Panic Disorders – 2 Protocols
53. Studies of Venlafaxine in Patients with Major Depressive Disorder – 6 Protocols

*Mohammad Bolouri*      27/AUG/2024  

---

Signature and Date

This page is a manifestation of an electronic record that was signed electronically.

**Document Name:** Flourish\_Investigator\_CV\_Mohammad Bolouri- Version  
27Aug2024

**Document ID:** 1470

**No. Pages:** 11

**Statement of Testament:** I approve the document

**Electronic Signature for:** Mohammad Bolouri

**Electronically Signed by:** mbolouri

**Date & Time:** 27/AUG/2024 4:57:06 PM EDT

**IP Address:** 24.172.71.142